FDA accepts Denali Therapeutics’ BLA for tividenofusp alfa

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Denali Therapeutics announced that the US Food and Drug Administration (FDA) has accepted and granted priority review to its Biologics License Application (BLA) for tividenofusp alfa, a potential enzyme replacement therapy for Hunter syndrome (MPS II). According to the company, the target action date under the Prescription Drug User Fee Act (PDUFA) is January 5, 2026.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE